The global clinical next-generation sequencing (NGS) market, valued at USD 6.2 billion in 2024, is expected to reach USD 15.2 billion by 2032 with a 13.6% CAGR. Growth drivers include personalized ...

The global companion diagnostics market is set to surge from USD 7.03 Billion in 2024 to USD 22.83 Billion by 2034, driven by rising cancer prevalence and precision medicine advancements. Key trends ...

The Philippine Genome Center (PGC)-Visayas underscored the contribution of ‘next-generation sequencing’ in the field of ...

The U.S. FDA has approved a new test for patients with lung cancer to match the correct individuals with a targeted treatment ...

Next-generation sequencing (NGS) has transformed immune profiling, enabling deeper characterization of disease mechanisms, ...

Panelists discuss how biomarker development in anal cancer remains limited with PD-L1 status not influencing treatment ...

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.

Brown Cancer Center recently became the first facility in the United States of America to offer its patients access to an FDA ...

A global team mapped over 100,000 structural variants in human genomes by applying Oxford Nanopore long-read sequencing and a ...

The roadmap was coauthored from key leaders of the Solana ecosystem and centers on ‘Application-Controlled Execution’ ...